New universal CAR-T therapy targets tough multiple myeloma cases

This early-stage study tests a new type of CAR-T cell therapy, called UWD-00B, for people with multiple myeloma that has come back or not responded to other treatments. The therapy uses donor cells that are modified to target and kill cancer cells, and does not require the patient's own cells. The main goals are to check if the treatment is safe and to find the best dose. About 30 adults aged 18 to 75 will receive a single infusion after a short chemotherapy prep, and they will be followed for at least five years to monitor effects and long-term outcomes.